Period | S | T | F | |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Visit | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 |
Week | 0 | 1a | 1 | 2 | 2 | 3 | 3 | 4 | 4 | 5 | 5 | 6 | 6b | 7c |
Eligibility test | â—‹ | |||||||||||||
Informed consent | â—‹ | |||||||||||||
Demographic characteristics | â—‹ | |||||||||||||
Random allocation | â—‹ | |||||||||||||
Treatment | â—‹ | â—‹ | â—‹ | â—‹ | â—‹ | â—‹ | â—‹ | â—‹ | â—‹ | â—‹ | â—‹ | â—‹ | ||
Serum metabolites | â—‹ | â—‹ | ||||||||||||
BIA | â—‹ | â—‹ | â—‹ | â—‹ | â—‹ | â—‹ | â—‹ | |||||||
WC/HC | â—‹ | â—‹ | â—‹ | â—‹ | â—‹ | â—‹ | â—‹ | |||||||
IPAQ | â—‹ | â—‹ | ||||||||||||
SRRS | â—‹ | â—‹ | ||||||||||||
SRI | â—‹ | â—‹ | ||||||||||||
FSS | â—‹ | â—‹ | â—‹ | â—‹ | â—‹ | â—‹ | â—‹ | |||||||
BDI | â—‹ | â—‹ | ||||||||||||
Urine metabolites | â—‹ | â—‹ | ||||||||||||
Adverse events | â—‹ | â—‹ | â—‹ | â—‹ | â—‹ | â—‹ | â—‹ | â—‹ | â—‹ | â—‹ | â—‹ | â—‹ | â—‹ | |
Credibility test | â—‹ |